Interestingly, combination use of JWH133 and CYP2J2 shRNA resulted in more potently retarded tumor growth than the respective effects in vivo (&&P < 0.01 vs. U87 + CYP2J2 shRNA, ##P < 0.01 vs. U87 + JWH133 + Control shRNA; Figures 5A, B). The gene discussed is CYP2J2; the disease is neoplasm.